Heterozygous defects in PAX6 gene and congenital hypopituitarism

Masaki Takagi, Keisuke Nagasaki, Ikuma Fujiwara, Tomohiro Ishii, Naoko Amano, Yumi Asakura, Koji Muroya, Yukihiro Hasegawa, Masanori Adachi, Tomonobu Hasegawa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The prevalence of congenital hypopituitarism (CH) attributable to known transcription factor mutations appears to be rare and other causative genes for CH remain to be identified. Due to the sporadic occurrence of CH, de novo chromosomal rearrangements could be one of the molecular mechanisms participating in its etiology, especially in syndromic cases.

Objective: To identify the role of copy number variations (CNVs) in the etiology of CH and to identify novel genes implicated in CH.

Subjects and methods: We enrolled 88 (syndromic: 30; non-syndromic: 58) Japanese CH patients. We performed an array comparative genomic hybridization screening in the 30 syndromic CH patients. For all the 88 patients, we analyzed PAX6 by PCR-based sequencing.

Results: We identified one heterozygous 310-kb deletion of the PAX6 enhancer region in one patient showing isolated GH deficiency (IGHD), cleft palate, and optic disc cupping. We also identified one heterozygous 6.5-Mb deletion encompassing OTX2 in a patient with bilateral anophthalmia and multiple pituitary hormone deficiency. We identified a novel PAX6 mutation, namely p.N116S in one non-syndromic CH patient showing IGHD. The p.N116S PAX6 was associated with an impairment of the transactivation capacities of the PAX6-binding elements.

Conclusions: This study showed that heterozygous PAX6 mutations are associated with CH patients. PAX6 mutations may be associated with diverse clinical features ranging from severely impaired ocular and pituitary development to apparently normal phenotype. Overall, this study identified causative CNVs with a possible role in the etiology of CH in <10% of syndromic CH patients.

Original languageEnglish
Pages (from-to)37-45
Number of pages9
JournalEuropean Journal of Endocrinology
Volume172
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Hypopituitarism
Genes
Pituitary Dwarfism
Mutation
Anophthalmos
Comparative Genomic Hybridization
Pituitary Hormones
Optic Disk
Cleft Palate
Transcriptional Activation
Transcription Factors

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Heterozygous defects in PAX6 gene and congenital hypopituitarism. / Takagi, Masaki; Nagasaki, Keisuke; Fujiwara, Ikuma; Ishii, Tomohiro; Amano, Naoko; Asakura, Yumi; Muroya, Koji; Hasegawa, Yukihiro; Adachi, Masanori; Hasegawa, Tomonobu.

In: European Journal of Endocrinology, Vol. 172, No. 1, 01.01.2015, p. 37-45.

Research output: Contribution to journalArticle

Takagi, M, Nagasaki, K, Fujiwara, I, Ishii, T, Amano, N, Asakura, Y, Muroya, K, Hasegawa, Y, Adachi, M & Hasegawa, T 2015, 'Heterozygous defects in PAX6 gene and congenital hypopituitarism', European Journal of Endocrinology, vol. 172, no. 1, pp. 37-45. https://doi.org/10.1530/EJE-14-0255
Takagi, Masaki ; Nagasaki, Keisuke ; Fujiwara, Ikuma ; Ishii, Tomohiro ; Amano, Naoko ; Asakura, Yumi ; Muroya, Koji ; Hasegawa, Yukihiro ; Adachi, Masanori ; Hasegawa, Tomonobu. / Heterozygous defects in PAX6 gene and congenital hypopituitarism. In: European Journal of Endocrinology. 2015 ; Vol. 172, No. 1. pp. 37-45.
@article{e17de2692f0d4e53996c65aff098e373,
title = "Heterozygous defects in PAX6 gene and congenital hypopituitarism",
abstract = "Background: The prevalence of congenital hypopituitarism (CH) attributable to known transcription factor mutations appears to be rare and other causative genes for CH remain to be identified. Due to the sporadic occurrence of CH, de novo chromosomal rearrangements could be one of the molecular mechanisms participating in its etiology, especially in syndromic cases.Objective: To identify the role of copy number variations (CNVs) in the etiology of CH and to identify novel genes implicated in CH.Subjects and methods: We enrolled 88 (syndromic: 30; non-syndromic: 58) Japanese CH patients. We performed an array comparative genomic hybridization screening in the 30 syndromic CH patients. For all the 88 patients, we analyzed PAX6 by PCR-based sequencing.Results: We identified one heterozygous 310-kb deletion of the PAX6 enhancer region in one patient showing isolated GH deficiency (IGHD), cleft palate, and optic disc cupping. We also identified one heterozygous 6.5-Mb deletion encompassing OTX2 in a patient with bilateral anophthalmia and multiple pituitary hormone deficiency. We identified a novel PAX6 mutation, namely p.N116S in one non-syndromic CH patient showing IGHD. The p.N116S PAX6 was associated with an impairment of the transactivation capacities of the PAX6-binding elements.Conclusions: This study showed that heterozygous PAX6 mutations are associated with CH patients. PAX6 mutations may be associated with diverse clinical features ranging from severely impaired ocular and pituitary development to apparently normal phenotype. Overall, this study identified causative CNVs with a possible role in the etiology of CH in <10{\%} of syndromic CH patients.",
author = "Masaki Takagi and Keisuke Nagasaki and Ikuma Fujiwara and Tomohiro Ishii and Naoko Amano and Yumi Asakura and Koji Muroya and Yukihiro Hasegawa and Masanori Adachi and Tomonobu Hasegawa",
year = "2015",
month = "1",
day = "1",
doi = "10.1530/EJE-14-0255",
language = "English",
volume = "172",
pages = "37--45",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - Heterozygous defects in PAX6 gene and congenital hypopituitarism

AU - Takagi, Masaki

AU - Nagasaki, Keisuke

AU - Fujiwara, Ikuma

AU - Ishii, Tomohiro

AU - Amano, Naoko

AU - Asakura, Yumi

AU - Muroya, Koji

AU - Hasegawa, Yukihiro

AU - Adachi, Masanori

AU - Hasegawa, Tomonobu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: The prevalence of congenital hypopituitarism (CH) attributable to known transcription factor mutations appears to be rare and other causative genes for CH remain to be identified. Due to the sporadic occurrence of CH, de novo chromosomal rearrangements could be one of the molecular mechanisms participating in its etiology, especially in syndromic cases.Objective: To identify the role of copy number variations (CNVs) in the etiology of CH and to identify novel genes implicated in CH.Subjects and methods: We enrolled 88 (syndromic: 30; non-syndromic: 58) Japanese CH patients. We performed an array comparative genomic hybridization screening in the 30 syndromic CH patients. For all the 88 patients, we analyzed PAX6 by PCR-based sequencing.Results: We identified one heterozygous 310-kb deletion of the PAX6 enhancer region in one patient showing isolated GH deficiency (IGHD), cleft palate, and optic disc cupping. We also identified one heterozygous 6.5-Mb deletion encompassing OTX2 in a patient with bilateral anophthalmia and multiple pituitary hormone deficiency. We identified a novel PAX6 mutation, namely p.N116S in one non-syndromic CH patient showing IGHD. The p.N116S PAX6 was associated with an impairment of the transactivation capacities of the PAX6-binding elements.Conclusions: This study showed that heterozygous PAX6 mutations are associated with CH patients. PAX6 mutations may be associated with diverse clinical features ranging from severely impaired ocular and pituitary development to apparently normal phenotype. Overall, this study identified causative CNVs with a possible role in the etiology of CH in <10% of syndromic CH patients.

AB - Background: The prevalence of congenital hypopituitarism (CH) attributable to known transcription factor mutations appears to be rare and other causative genes for CH remain to be identified. Due to the sporadic occurrence of CH, de novo chromosomal rearrangements could be one of the molecular mechanisms participating in its etiology, especially in syndromic cases.Objective: To identify the role of copy number variations (CNVs) in the etiology of CH and to identify novel genes implicated in CH.Subjects and methods: We enrolled 88 (syndromic: 30; non-syndromic: 58) Japanese CH patients. We performed an array comparative genomic hybridization screening in the 30 syndromic CH patients. For all the 88 patients, we analyzed PAX6 by PCR-based sequencing.Results: We identified one heterozygous 310-kb deletion of the PAX6 enhancer region in one patient showing isolated GH deficiency (IGHD), cleft palate, and optic disc cupping. We also identified one heterozygous 6.5-Mb deletion encompassing OTX2 in a patient with bilateral anophthalmia and multiple pituitary hormone deficiency. We identified a novel PAX6 mutation, namely p.N116S in one non-syndromic CH patient showing IGHD. The p.N116S PAX6 was associated with an impairment of the transactivation capacities of the PAX6-binding elements.Conclusions: This study showed that heterozygous PAX6 mutations are associated with CH patients. PAX6 mutations may be associated with diverse clinical features ranging from severely impaired ocular and pituitary development to apparently normal phenotype. Overall, this study identified causative CNVs with a possible role in the etiology of CH in <10% of syndromic CH patients.

UR - http://www.scopus.com/inward/record.url?scp=84920369357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920369357&partnerID=8YFLogxK

U2 - 10.1530/EJE-14-0255

DO - 10.1530/EJE-14-0255

M3 - Article

VL - 172

SP - 37

EP - 45

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 1

ER -